Literature DB >> 7884887

Chimeras from a human rhinovirus 14-human immunodeficiency virus type 1 (HIV-1) V3 loop seroprevalence library induce neutralizing responses against HIV-1.

D A Resnick1, A D Smith, S C Gesiler, A Zhang, E Arnold, G F Arnold.   

Abstract

A chimeric virus library was designed whereby sequences corresponding to the V3 loop of human immunodeficiency virus type 1 (HIV-1) were presented on the surface of human rhinovirus 14. The V3 loop sequences consisted of a relatively conserved segment of seven amino acids and five adjacent residues that were allowed to vary in proportion to their seroprevalence among HIV-1 isolates of North America and Europe. A technique called random systematic mutagenesis was used to incorporate the composite V3 loop sequences flanked by zero to two randomized amino acids. This library could contain 2.7 x 10(8) members having diverse sequences and conformations. Immunoselection of a portion of this library by using two neutralizing V3 loop-directed monoclonal antibodies followed by selection for desirable growth and purification characteristics yielded a set of chimeric rhinoviruses, five of which are described. The inserted sequences in the five chimeras do not match those of any known isolate of HIV-1. Nonetheless, all five chimeras were neutralized by antibodies directed against different strains of HIV-1 and were able to elicit the production of antibodies that bind V3 loop peptides from diverse HIV-1 isolates. Moreover, antisera derived from four of the five chimeras were capable of neutralizing one or more strains of HIV-1 in cell culture. This study demonstrates that random systematic mutagenesis in conjunction with antibody screening is a powerful and efficient means to obtain antigenic chimeras with relevant immunogenic properties.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7884887      PMCID: PMC188914     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  43 in total

1.  Broadly neutralizing monoclonal antibodies to the V3 region of HIV-1 can be elicited by peptide immunization.

Authors:  M E White-Scharf; B J Potts; L M Smith; K A Sokolowski; J R Rusche; S Silver
Journal:  Virology       Date:  1993-01       Impact factor: 3.616

2.  Crystal structure of the principal neutralization site of HIV-1.

Authors:  J B Ghiara; E A Stura; R L Stanfield; A T Profy; I A Wilson
Journal:  Science       Date:  1994-04-01       Impact factor: 47.728

3.  Use of random systematic mutagenesis to generate viable human rhinovirus 14 chimeras displaying human immunodeficiency virus type 1 V3 loop sequences.

Authors:  A D Smith; D A Resnick; A Zhang; S C Geisler; E Arnold; G F Arnold
Journal:  J Virol       Date:  1994-01       Impact factor: 5.103

4.  Development of cowpea mosaic virus as a high-yielding system for the presentation of foreign peptides.

Authors:  C Porta; V E Spall; J Loveland; J E Johnson; P J Barker; G P Lomonossoff
Journal:  Virology       Date:  1994-08-01       Impact factor: 3.616

5.  Chimeric influenza virus induces neutralizing antibodies and cytotoxic T cells against human immunodeficiency virus type 1.

Authors:  S Li; V Polonis; H Isobe; H Zaghouani; R Guinea; T Moran; C Bona; P Palese
Journal:  J Virol       Date:  1993-11       Impact factor: 5.103

6.  Design and construction of rhinovirus chimeras incorporating immunogens from polio, influenza, and human immunodeficiency viruses.

Authors:  G F Arnold; D A Resnick; Y Li; A Zhang; A D Smith; S C Geisler; A Jacobo-Molina; W Lee; R G Webster; E Arnold
Journal:  Virology       Date:  1994-02       Impact factor: 3.616

7.  Structure determination of antiviral compound SCH 38057 complexed with human rhinovirus 14.

Authors:  A Zhang; R G Nanni; T Li; G F Arnold; D A Oren; A Jacobo-Molina; R L Williams; G Kamer; D A Rubenstein; Y Li
Journal:  J Mol Biol       Date:  1993-04-05       Impact factor: 5.469

8.  Use of monoclonal antibodies to identify four neutralization immunogens on a common cold picornavirus, human rhinovirus 14.

Authors:  B Sherry; A G Mosser; R J Colonno; R R Rueckert
Journal:  J Virol       Date:  1986-01       Impact factor: 5.103

9.  Neutralization of divergent human immunodeficiency virus type 1 variants and primary isolates by IAM-41-2F5, an anti-gp41 human monoclonal antibody.

Authors:  A J Conley; J A Kessler; L J Boots; J S Tung; B A Arnold; P M Keller; A R Shaw; E A Emini
Journal:  Proc Natl Acad Sci U S A       Date:  1994-04-12       Impact factor: 11.205

Review 10.  Libraries of human rhinovirus-based HIV vaccines generated using random systematic mutagenesis.

Authors:  D A Resnick; A D Smith; A Zhang; S C Geisler; E Arnold; G F Arnold
Journal:  AIDS Res Hum Retroviruses       Date:  1994       Impact factor: 2.205

View more
  11 in total

1.  Human rhinovirus type 14:human immunodeficiency virus type 1 (HIV-1) V3 loop chimeras from a combinatorial library induce potent neutralizing antibody responses against HIV-1.

Authors:  A D Smith; S C Geisler; A A Chen; D A Resnick; B M Roy; P J Lewi; E Arnold; G F Arnold
Journal:  J Virol       Date:  1998-01       Impact factor: 5.103

Review 2.  Cowpea mosaic virus as a vaccine carrier of heterologous antigens.

Authors:  F R Brennan; T D Jones; W D Hamilton
Journal:  Mol Biotechnol       Date:  2001-01       Impact factor: 2.695

3.  Antigenic characteristics of rhinovirus chimeras designed in silico for enhanced presentation of HIV-1 gp41 epitopes [corrected].

Authors:  Mauro Lapelosa; Gail Ferstandig Arnold; Emilio Gallicchio; Eddy Arnold; Ronald M Levy
Journal:  J Mol Biol       Date:  2010-02-04       Impact factor: 5.469

4.  Mimicking the structure of the V3 epitope bound to HIV-1 neutralizing antibodies.

Authors:  Amit Mor; Eugenia Segal; Brenda Mester; Boris Arshava; Osnat Rosen; Fa-Xiang Ding; Joseph Russo; Amnon Dafni; Fabian Schvartzman; Tali Scherf; Fred Naider; Jacob Anglister
Journal:  Biochemistry       Date:  2009-04-21       Impact factor: 3.162

5.  Broad neutralization of human immunodeficiency virus type 1 (HIV-1) elicited from human rhinoviruses that display the HIV-1 gp41 ELDKWA epitope.

Authors:  Gail Ferstandig Arnold; Paola K Velasco; Andrew K Holmes; Terri Wrin; Sheila C Geisler; Pham Phung; Yu Tian; Dawn A Resnick; Xuejun Ma; Thomas M Mariano; Christos J Petropoulos; John W Taylor; Hermann Katinger; Eddy Arnold
Journal:  J Virol       Date:  2009-03-11       Impact factor: 5.103

6.  Chimeric plant virus particles administered nasally or orally induce systemic and mucosal immune responses in mice.

Authors:  F R Brennan; T Bellaby; S M Helliwell; T D Jones; S Kamstrup; K Dalsgaard; J I Flock; W D Hamilton
Journal:  J Virol       Date:  1999-02       Impact factor: 5.103

7.  In silico vaccine design based on molecular simulations of rhinovirus chimeras presenting HIV-1 gp41 epitopes.

Authors:  Mauro Lapelosa; Emilio Gallicchio; Gail Ferstandig Arnold; Eddy Arnold; Ronald M Levy
Journal:  J Mol Biol       Date:  2008-11-08       Impact factor: 5.469

8.  HIV antigen incorporation within adenovirus hexon hypervariable 2 for a novel HIV vaccine approach.

Authors:  Qiana L Matthews; Aiman Fatima; Yizhe Tang; Brian A Perry; Yuko Tsuruta; Svetlana Komarova; Laura Timares; Chunxia Zhao; Natalia Makarova; Anton V Borovjagin; Phoebe L Stewart; Hongju Wu; Jerry L Blackwell; David T Curiel
Journal:  PLoS One       Date:  2010-07-27       Impact factor: 3.240

Review 9.  Use of macromolecular assemblies as expression systems for peptides and synthetic vaccines.

Authors:  G P Lomonossoff; J E Johnson
Journal:  Curr Opin Struct Biol       Date:  1996-04       Impact factor: 6.809

10.  Chimeric rhinoviruses displaying MPER epitopes elicit anti-HIV neutralizing responses.

Authors:  Guohua Yi; Mauro Lapelosa; Rachel Bradley; Thomas M Mariano; Denise Elsasser Dietz; Scott Hughes; Terri Wrin; Chris Petropoulos; Emilio Gallicchio; Ronald M Levy; Eddy Arnold; Gail Ferstandig Arnold
Journal:  PLoS One       Date:  2013-09-06       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.